Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fisogatinib (BLU-554) in Hepatocellular Carcinoma
NCT02508467Phase 1Completed
- Sponsor
- Blueprint Medicines
- Start
- Jul 2015
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, open-label, single-arm trial of fisogatinib in hepatocellular carcinoma (HCC), sponsored by Blueprint Medicines. Primary endpoints: Maximum Tolerated Dose, Recommended Phase 2 Dose up to 24 months and 1 more. Started Jul 2015; status: completed.
02
Drugs
fisogatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02508467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508467.